Tissue Transglutaminase Test Market to grow at a CAGR of 18.98% during 2025 to 2035; Driven by Increasing Awareness of Celiac Disease and Advancements in Diagnostic Testing Technologies

Market Research Future (MRFR)’s latest study reveals that the Global Tissue Transglutaminase Test Market is projected to grow significantly from USD 7.50 billion in 2025 to USD 42.65 billion by 2035, registering a compound annual growth rate (CAGR) of 18.98% during the forecast period (2025–2035), after being estimated at USD 6.31 billion in 2024. The market expansion is driven by increasing awareness of celiac disease, technological advancements in testing methods, and a broader shift towards preventive healthcare.

Prominent market participants operating in the global tissue transglutaminase test market include Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), QuidelOrtho Corporation (US), Hoffmann-La Roche (CH), and Genova Diagnostics (US). These companies are actively investing in research, expanding diagnostic capabilities, and forming strategic partnerships to enhance their market presence.

Market Highlights

The global tissue transglutaminase test market is witnessing accelerated growth, primarily fueled by the rise in autoimmune disorders and the demand for accurate diagnostic tools. The market stood at USD 6.31 billion in 2024 and is expected to reach USD 42.65 billion by 2035, reflecting growing clinical preference for precise celiac disease screening. The strong focus on early detection, coupled with supportive regulatory guidelines, has been a key growth catalyst.

The healthcare sector plays a vital role in this evolution, with laboratories and hospitals adopting automated systems and high-throughput screening. For instance, major diagnostics leaders are continuously innovating to improve test sensitivity and reduce result turnaround times. Technological innovations such as automated testing systems and the integration of artificial intelligence in data analysis are enhancing diagnostic capabilities, making it easier for clinicians to identify celiac disease and related disorders.

Browse Full Report: https://www.marketresearchfuture.com/reports/tissue-transglutaminase-test-market-824

Segment Analysis

The Tissue Transglutaminase Test Market, by type, is segmented into Serological Testing, Biopsy, and Others. The Serological Testing segment held the majority share and continues to dominate global market revenues due to its non-invasive nature, ease of use, and high sensitivity for detecting antibodies. Meanwhile, the Biopsy segment is witnessing rapid growth as a critical diagnostic tool, providing definitive histological evidence in complex cases.

By End-User, the market is bifurcated into Clinics and Hospitals, Home Care, Research Organizations, and Others. The Clinics and Hospitals segment dominated the global market and is projected to remain a leading category through established infrastructure and steady demand. On the other hand, the Home Care segment is emerging as the fastest-growing category, driven by advancements in at-home diagnostic kits that enhance patient convenience and autonomy.

Regional Analysis

Regionally, the global tissue transglutaminase test market is segmented into North America, Europe, Asia-Pacific, and the Middle East and Africa.

North America represents the largest market, accounting for approximately 45% of the global share. Growth is driven by advanced healthcare infrastructure, high prevalence of celiac disease, and supportive FDA policies.

Europe stands as the second-largest market, holding around 30% of the global share, fueled by rising awareness of autoimmune conditions and proactive regulatory frameworks from the EMA. Countries like Germany, France, and the UK lead the regional adoption of advanced diagnostic technologies.

Asia-Pacific is projected to record the fastest growth, contributing roughly 20% to the global market. This expansion is supported by rising healthcare investments, a large population base, and growing medical infrastructure across countries like China, India, and Japan.

Middle East and Africa accounts for about 5% of the market, gradually emerging through healthcare improvements and increasing disease awareness, led by countries like South Africa and the UAE.

Key Findings of the Study

• The Tissue Transglutaminase Test Market is projected to grow from USD 7.50 billion in 2025 to USD 42.65 billion by 2035, registering a CAGR of 18.98%.


• Rising awareness of celiac disease and an increasing incidence of autoimmune disorders are major growth drivers.


• Serological testing dominates the market share due to its non-invasive nature and high sensitivity.


• The Clinics and Hospitals segment remains the leading end-use category, while Home Care emerges as the fastest-growing.


• North America leads the global market, whereas Asia-Pacific is positioned as the fastest-growing regional market.


• Key market participants include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers.


• Technological innovations, such as automated systems and AI integration, are reshaping diagnostic accuracy and efficiency.


• Regulatory guidelines and a strong shift toward preventive healthcare continue to provide momentum for market adoption.